TNF and cancer: A Swedish nationwide study documented modest excess cancer cases with anti-TNF therapy (2.7 per 1000 person-years; HR = 1.41, 95% CI 1.24–1.62), primarily due to colorectal and hepatobiliary cancers, likely reflecting more aggressive disease rather than therapy [65].